-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20

Benzinga·07/24/2026 12:51:57
Listen to the news
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $18 to $20.